Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT06264492
Starting soon Observational

Delving Into Participation Trends of Scleroderma Clinical Trials

NCT06264492 · tracked via the Priya Life Science USA tracker
Sponsor
Power Life Sciences Inc
Phase
Observational
Started
2025-03
Last updated
2024-02-28

Condition(s) studied

Scleroderma

Study summary

Typically, specific demographic subsets tend to exhibit greater engagement in medical research. Nonetheless, there is insufficient research elucidating the trial characteristics influencing the participation of these particular demographics.

The study will analyze data from diverse demographic viewpoints to uncover recurring trends that could provide valuable insights for future patients with scleroderma.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient has been diagnosed with scleroderma * Patient has self-identified as planning to enroll in an observational clinical trial * Patient is a minimum of 18 years or older Exclusion Criteria: * Patient is pregnant * Inability to perform regular electronic reporting * Patient does not understand, sign, and return consent form

Primary outcome measure(s)

  • Rate of patients in clinical research for scleroderma — 3 months
  • Number of scleroderma study participants who stay committed until clinical study wraps up — 12 months

Trial sites (1)

FacilityCityRegionStatus
Power Life Sciences San Francisco California

More Power Life Sciences Inc. trials in the USA

Understanding Participation Habits Among Plaque Psoriasis Patients Starting soon
Investigative Analysis of Soft Tissue Sarcoma Clinical Trials: An Observational Study Starting soon
Revealing Engagement Dynamics Among Semantic Dementia Patients Starting soon
A Journey Into Participation Patterns Among Patients With Hidradenitis Suppurativa Starting soon
Evaluating the Occurrence of Participation Trends Among Weight Loss Clinical Trials Patients Starting soon

Other trials for the same condition

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) Active, not recruiting
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis Recruiting
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06264492 on ClinicalTrials.gov ↗ ← All trials in the USA